BET inhibition targets ABC-DLBCL constitutive B-cell receptor signaling through PAX5

Autor: Derek B Oien, Samanta Sharma, Maureen M. Hattersley, Michelle M. DuPont, Steven W Criscione, Laura B Prickett, Anne U Goeppert, Lisa Drew, Yi Yao, Jingwen Zhang, Ho Man Chan

Publikováno v: Blood Advances.

B-cell receptor (BCR) signaling is essential for the diffuse large B-cell lymphoma (DLBCL) subtype that originates from activated B-cells (ABC). ABC-DLBCL cells are sensitive to Bruton tyrosine kinase intervention. However, relapsed or refractory ABC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff4345f737f0a4edfc8eae5489d49ba4
https://doi.org/10.1182/bloodadvances.2022009257

Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

Autor: Richard Wooster, Mark T. Bilodeau, Beata Sweryda-Krawiec, Rajesh Shinde, Gitanjali Sharma, Benoît Moreau, Samantha Perino, Patrick Lim Soo, Charles-Andre Lemelin, James Gifford, Haley Oller, Michelle M. DuPont, Adam Brockman, Patrick Bazinet, Tsun P. Au Yeung, Rossitza Alargova, Kristina Kriksciukaite, James M. Quinn, Brian H. White, Kerry A. Whalen

Pharmacokinetic analysis of PEN-221 and DM1 in non-tumor bearing mice

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ba22bdfd82befebd5572cd48a27bdaf
https://doi.org/10.1158/1535-7163.22506007

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Autor: Lawson M; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Cureton N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Ros S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Cheraghchi-Bashi A; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Urosevic J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., D'Arcy S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Delpuech O; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., DuPont M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fisher DI; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Lewis H; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Trueman D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Wali N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Williamson SC; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Moss J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Montaudon E; Institut Curie, Paris, France., Derrien H; Institut Curie, Paris, France., Marangoni E; Institut Curie, Paris, France., Miragaia RJ; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gagrica S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Morentin-Gutierrez P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Moss TA; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Maglennon G; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Sutton D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Polanski R; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Rosen A; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cairns J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Zhang P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Critchlow SE; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Scott JS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Lindemann JPO; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Barry ST; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Morrow CJ; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Carnevalli LS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2023 Dec 01; Vol. 83 (23), pp. 3989-4004.

A pharmacokinetic-pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti-tumour activity.

Autor: Jones RDO; Oncology R&D, Research and Early Development, AstraZeneca, Cambridge, UK., Grondine M; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Borodovsky A; Formerly Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., San Martin M; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., DuPont M; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., D'Cruz C; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Schuller A; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Henry R; Formerly Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Barry E; Formerly Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Castriotta L; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Anjum R; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Petersson K; qPharmetra LLC, Stockholm, Sweden., Sahota T; BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK., Ahmed GF; Formerly BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2021 Feb; Vol. 178 (3), pp. 600-613. Date of Electronic Publication: 2020 Dec 07.

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitors.

Autor: Peterson EA; Medicinal Chemistry, Amgen Inc., 360 Binney St., Cambridge, MA 02142, USA. epeterso@amgen.com, Boezio AA, Andrews PS, Boezio CM, Bush TL, Cheng AC, Choquette D, Coats JR, Colletti AE, Copeland KW, DuPont M, Graceffa R, Grubinska B, Kim JL, Lewis RT, Liu J, Mullady EL, Potashman MH, Romero K, Shaffer PL, Stanton MK, Stellwagen JC, Teffera Y, Yi S, Cai T, La DS

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2012 Aug 01; Vol. 22 (15), pp. 4967-74. Date of Electronic Publication: 2012 Jun 16.